A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
about
Risperidone (depot) for schizophreniaIntermittent drug techniques for schizophreniaRisperidone versus placebo for schizophreniaAtypical antipsychotics for people with both schizophrenia and depressionA comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophreniaLong-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic reviewRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesComparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsDefinitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewEfficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled StudyEfficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Modern antipsychotic drugs: a critical overviewEffectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialPartial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysisA Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaWeight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Antipsychotic Maintenance Treatment: Time to Rethink?The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment.Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methodsThe recognition and optimal management of early psychosis: an evidence-based reform.Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Weight gain profiles of new anti-psychotics: public health consequences.Novel antipsychotics in the long-term treatment of schizophrenia.Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia.Quantifying clinical relevance in the treatment of schizophrenia.Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
P2860
Q24185901-A721A6AA-BCEE-4B15-96E7-8977C6400F73Q24201124-E1E6ECDE-6753-4E75-BF5A-40481A78FCDCQ24241041-986CABAF-F9FC-45AE-8F35-639630AA630BQ24242037-0B2D077F-169B-4967-B1C0-DC6041247B17Q24794849-9DFDCCFD-F000-4CC6-909F-2DCB5F8A6B95Q26770497-4C1DD653-7FF0-4410-904E-6A5C03B003DDQ26863435-6CC5497F-4D72-4661-8E49-0EB96B49D20AQ27320151-FA59B6B1-15BF-402B-8D6A-4F559E56EF31Q33223628-6A7C3A00-CE10-414D-A65E-17751B131D8AQ33235110-33F1FFE3-A028-4342-B910-D62230F549A0Q33256430-0A362745-3264-4BAE-8592-E620AFCBB0AFQ33566124-8153C570-9546-4384-B14A-54EAEF6A9772Q33589087-D4D10A17-2E56-4953-B701-2EAFFD5A7AF6Q33625354-251ECB56-2B8C-4DCA-A6AB-B61F214D8954Q33738740-55644F21-8774-431B-BC5F-46BA951D7500Q33814003-240754CF-C27D-46F3-9037-289C27945370Q33853390-A5675468-9B8D-4C93-A74E-D37255840FB6Q33914295-10DAEE16-4113-4BE9-AD16-CF05EB2137A6Q33932365-C3B42807-827A-4F61-9664-39C853AB42A5Q34075734-7117E281-A43B-4B0E-BF9C-30F85E7091E2Q34315836-93C76BE5-D1D8-4402-B3D6-992C8C677CE1Q34329113-03BC54CF-D254-4898-90D9-D203E9CF1A41Q34337272-A64755B5-84AE-4D17-9A66-685444811259Q34386214-FF856F33-FD58-4177-9402-E5B43F665473Q34393431-42F1FEC5-8F3E-4016-9060-E67BF9C2E27EQ34444162-EAC9C8F9-7925-40D3-8065-A30822987893Q34486175-497A638B-420D-4908-A470-45B0B946D5C4Q34488215-A5A8A116-FA21-47DE-A7C9-73EA060F9590Q34550618-C40E92A1-00EF-44D9-B0F5-D64923E5ECD8Q34660553-69D4BC12-EE5D-4A27-A26F-2C75C87973AFQ34669624-9500CD17-CA35-474C-BD1D-AC73F6378354Q34722226-BF78FFC5-3DB4-43B1-856E-11A2D0F05232Q34879022-D266442B-62DF-44D6-AE38-2994C9532102Q35030003-96EEDAA8-50E9-46DC-AEB0-53FD64C48AB1Q35143555-0FF1B699-94A3-4382-B933-06564F084A0FQ35198895-9DDD5087-4027-4E45-827C-4B22F1BF604BQ35719339-60315528-D684-4996-8183-E60176919FFDQ35738958-BFF5FB8A-2B05-4BF6-AB32-AF0DB7AA3F92Q35819467-D37C3146-ACF9-4B52-983D-DBA60833861FQ35873789-43856049-57B9-4D5D-9E94-E8F78CFE6B0E
P2860
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A comparison of risperidone an ...... n patients with schizophrenia.
@en
A comparison of risperidone an ...... n patients with schizophrenia.
@nl
type
label
A comparison of risperidone an ...... n patients with schizophrenia.
@en
A comparison of risperidone an ...... n patients with schizophrenia.
@nl
prefLabel
A comparison of risperidone an ...... n patients with schizophrenia.
@en
A comparison of risperidone an ...... n patients with schizophrenia.
@nl
P2093
P356
P1476
A comparison of risperidone an ...... n patients with schizophrenia.
@en
P2093
John G Csernansky
Ramy Mahmoud
Risperidone-USA-79 Study Group
Ronald Brenner
P356
10.1056/NEJMOA002028
P407
P577
2002-01-01T00:00:00Z